These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32705125)

  • 21. [Chinese expert-based consensus for methotrexate in rheumatic diseases].
    Chinese Association of Rheumatology and Immunology Physicians
    Zhonghua Nei Ke Za Zhi; 2018 Oct; 57(10):719-722. PubMed ID: 30293331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why is methotrexate the first selection in disease-modifying antirheumatic drug therapy? Comment on the article by Wolfe et al.
    Caballero-Uribe CV
    Arthritis Care Res; 1999 Apr; 12(2):152. PubMed ID: 10513503
    [No Abstract]   [Full Text] [Related]  

  • 23. Methotrexate embryopathy after exposure to low weekly doses in early pregnancy.
    Martín MC; Barbero P; Groisman B; Aguirre MÁ; Koren G
    Reprod Toxicol; 2014 Jan; 43():26-9. PubMed ID: 24513926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rheumatic syndromes caused by antirheumatic drugs.
    Rooney PJ; Bálint GP; Szebenyi B; Petrou P
    Baillieres Clin Rheumatol; 1991 Apr; 5(1):139-73. PubMed ID: 1676937
    [No Abstract]   [Full Text] [Related]  

  • 25. Methotrexate hepatotoxicity.
    West SG
    Rheum Dis Clin North Am; 1997 Nov; 23(4):883-915. PubMed ID: 9361160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 27. Paternity desire during rheumatic diseases under DMARDs: Information of patients and neonatal consequences in a French cohort of 156 patients.
    Larid G; Brigaud A; Bergeal E; Gervais E
    Joint Bone Spine; 2023 Jan; 90(1):105458. PubMed ID: 36108902
    [No Abstract]   [Full Text] [Related]  

  • 28. [Gastrointestinal side effects in the therapy of rheumatologic diseases].
    Schiemann U; Kellner H
    Z Gastroenterol; 2002 Nov; 40(11):937-43. PubMed ID: 12436372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease.
    Moitra RK; Ledingham JM; Hull RG; McCrae FC; Thomas AL; Shaban R; Mackay KR
    Rheumatology (Oxford); 2005 Feb; 44(2):256-7. PubMed ID: 15637036
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.
    Stamp LK; Roberts RL
    Pharmacogenomics; 2011 Oct; 12(10):1449-63. PubMed ID: 22008049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose and high-dose methotrexate are two different drugs in practical terms.
    Malaviya AN; Sharma A; Agarwal D; Kapoor S; Garg S; Sawhney S
    Int J Rheum Dis; 2010 Oct; 13(4):288-93. PubMed ID: 21199463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases.
    Mori S; Hidaka M; Kawakita T; Hidaka T; Tsuda H; Yoshitama T; Migita K; Ueki Y
    PLoS One; 2016; 11(4):e0154744. PubMed ID: 27128679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al.
    Besada E
    Arthritis Rheum; 2012 Feb; 64(2):596-7; author reply 597. PubMed ID: 22034076
    [No Abstract]   [Full Text] [Related]  

  • 34. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists.
    Gossec L; Bijlsma JW; Bombardier C; Canhão H; Devlin J; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Ostergaard M; Pereira IA; Ramos-Remus C; Zochling J; Dougados M
    Ann Rheum Dis; 2011 Feb; 70(2):388-9. PubMed ID: 20472594
    [No Abstract]   [Full Text] [Related]  

  • 35. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.
    Weber-Schoendorfer C; Chambers C; Wacker E; Beghin D; Bernard N; ; Shechtman S; Johnson D; Cuppers-Maarschalkerweerd B; Pistelli A; Clementi M; Winterfeld U; Eleftheriou G; Pupco A; Kao K; Malm H; Elefant E; Koren G; Vial T; Ornoy A; Meister R; Schaefer C
    Arthritis Rheumatol; 2014 May; 66(5):1101-10. PubMed ID: 24470106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evidence based medicine in rheumatology].
    Gause A; Raspe HH
    Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877
    [No Abstract]   [Full Text] [Related]  

  • 37. Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
    Espinoza F; Le Blay P; Combe B
    J Rheumatol; 2017 Jun; 44(6):844-849. PubMed ID: 28412711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).
    Furst DE; Keystone EC; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Burmester GR; Crofford LJ; Kavanaugh A
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii2-5. PubMed ID: 11890647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward a better understanding of methotrexate.
    Kremer JM
    Arthritis Rheum; 2004 May; 50(5):1370-82. PubMed ID: 15146406
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of MTX in the elderly and in patients with compromised renal function.
    Morgacheva O; Furst DE
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S85-94. PubMed ID: 21044439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.